Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) had its price target raised by analysts at B. Riley from $32.00 to $46.00. They now have a "buy" rating on the stock.
Arrowhead Pharmaceuticals, Inc. (ARWR)
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arrowheadpharma.com/investor-relations
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
ARWR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARWR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARWR alerts
High impacting Arrowhead Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARWR
News
- Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA NephropathyBusiness Wire
- Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic DiseasesBusiness Wire
- Hypertriglyceridemia Pipeline Market Research 2025: Comprehensive Review on 18+ Companies and 20+ Pipeline Drugs [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) [Yahoo! Finance]Yahoo! Finance
ARWR
Earnings
- 2/10/25 - Miss
ARWR
Sec Filings
- 3/7/25 - Form 424B7
- 3/5/25 - Form 4
- 3/4/25 - Form 144
- ARWR's page on the SEC website